PaxVax, Redwood City, CA

PaxVax

www.paxvax.com

PaxVax is a privately held, fully integrated vaccine company, based in Redwood City, California, USA. Established in 2007, in response to the global threat of the H5N1 pandemic, our founders set out to develop and commercialize an innovative vaccine technology in a socially responsible manner for global impact. Our founding principles were to enable geographically distributed manufacturing of affordable, self-administered oral vaccines against infectious diseases such as influenza. Since then, we have expanded our capabilities and technologies to address unmet vaccine needs against endemic diseases in developing countries, for travelers to disease-laden areas and in biodefense. Our clinical stage portfolio today includes vaccine candidates for cholera, avian influenza (H5N1), anthrax, and HIV. We are committed to providing both attractive financial returns and social returns, without a significant trade-off between the two. As a double bottom line business, we will measure our financial success in terms of return on equity and we will assess our social returns by access to our vaccines globally, particularly to the poor and otherwise disenfranchised. We strive to develop and deliver vaccines that are affordable and deliverable anywhere in the world regardless of the state of medical infrastructure or supply chains. We utilize investment capital as well as R&D grants and contracts to fund the development of our vaccines. We exploit the inherent synergies in our proprietary oral vaccine technology platform to research and develop multiple vaccine candidates in a timely and capital efficient manner. We strive to make an impact on infectious disease morbidity and mortality throughout the world and on the global vaccine industry through our successes. To date, we have raised more than $75 million (USD) from investors including Ignition Ventures, Ignition Growth and the Wellcome Trust. We are supported by R&D grants and contracts from the U.S. National Institutes of Health (NIH) through both its National Institutes of Allergy and Infectious Diseases (NIAID) and Division of AIDS (DAIDS) as well as the Bill & Melinda Gates Foundation. Our most advanced vaccine is a single dose oral cholera vaccine, which entered final or Phase III clinical trials, and whose study should be completed in 2014. Following this candidate is a vaccine ready for Phase II (Pandemic Influenza), two caccines in current Phase I studies (HIV and anthrax), and multiple candidates in preclinical research (HSV, dengue, malaria). PaxVax is headquartered in Redwood City, California and is incorporated in Delaware. Our laboratory and manufacturing facilities and the majority of our 80 employees are located in San Diego, California.

More>>

Number of Employees: 250-1000
Annual Revenue: $10-50 Million

www.paxvax.com
900 Veterans Boulevard Suite 500
Redwood City, CA USA 94063
Phone: 650.847.1075

Similar Companies

PreventionGenetics

Founded in 2004 and located in Marshfield, Wisconsin, PreventionGenetics is a CLIA and ISO 15189:2012 accredited clinical DNA testing laboratory.

Adagio Therapeutics

Adagio Therapeutics, Inc` is a clinical-stage a biotechnology company developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional pre-emergent coronaviruses` Our candidates are optimized using Adimab’s industry-leading antibody engineering capabilities and are designed to provide patients and clinicians with an unsurpassed combination of potency, breadth, durable protection (via half-life extension), manufacturability, tolerability, and affordability` Our portfolio of SARS-CoV-2 antibodies includes multiple, non-competing antibodies with distinct binding epitopes` Pre-clinical data show that our lead antibody ADG20 matches or exceeds the potency and coverage of other clinical SARS-CoV-2 antibody programs` We plan to advance ADG20 aggressively through global clinical trials for both the prevention and treatment of symptomatic COVID-19 and anticipate data from both prevention and treatment clinical trials in 2021` Adagio has secured manufacturing capacity for the production of ADG20 with third party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch`

Nightingale Health

Nightingale Health is a health technology company transforming preventive care. We envisage a world that focuses on keeping people healthy rather than just treating illnesses. The wide-ranging disease risk predictions provided by Nightingale consist of two interconnected factors: The extensive blood analysis technology developed by Nightingale and a large amount of data on health events. Nightingale helps people make better personal health decisions and connects the health industry to offer their services for individuals preventative needs. By empowering the world with comprehensive health insights, we accelerate scientific discoveries, industry developments and improve personal health for everyone. We`re a team of 60 members––a diverse bunch with interdisciplinary expertise in business, marketing, computational medicine, data science, healthcare, IT, design and more––who envisage a world that focuses on keeping people healthy rather than just treating illnesses. So, if you are looking to enable good tech that could make a real difference, Nightingale is the place to be

ImmunoGen

Targeting a better life for people with cancer is why we get up in the morning. It`s not enough to disrupt the progress of someone`s cancer; we want to keep cancer from disrupting someone`s life. That`s why everything we do is about developing the most precise, targeted cancer therapies. We believe this is the best way to get people back to their lives—back to living today, tomorrow, and beyond. Because for us, targeting a better now is the only thing that matters. ImmunoGen is a leader in developing antibody-drug conjugates (ADCs). Our lead product candidate, mirvetuximab soravtansine, is a first-in-class folate receptor alpha (FRα)-targeting ADC with multiple studies underway in ovarian cancer. Our second pivotal program, IMGN632, is a CD123-targeting ADC being studied as a monotherapy in BPDCN and in combination in AML. Our earlier-stage assets in development are IMGC936, an ADAM9-targeting ADC in co-development with MacroGenics, and IMGN151, our next generation anti-folate receptor alpha ADC.

Peptilogics

Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics. Through their computational platform, Peptilogics is radically altering drug discovery by not only uncovering new, previously unexplored chemical design space, but ensuring that each potential therapeutic is biologically viable and scalable to manufacture. Peptilogics` lead clinical stage peptide therapeutic, PLG0206, is a novel, broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for its initial focus on the treatment of prosthetic joint infections, an unmet medical need.

CTOs on the Move